More tools:Markets·Screener·Research·Chat

Glaukos Corporation (GKOS) Financial Statements

Glaukos Corporation
SIC 3841 · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
FIGI BBG001T91NX8
XNYS · usd
185.04▲ 7.57 (4.27%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close177.47
Day's Range172.98 – 185.35
52-Week Range73.16 – 191.62
Volume1.2M
Avg Volume836.7K
Share Statistics
Shares Outstanding
Employees1,094
ExchangeXNYS
Listed2015-06-25
Share count as of July 28, 2026
Loading Income Statement…
Key questions about Glaukos Corporation (GKOS)
What is Glaukos Corporation's Market Cap?
Glaukos Corporation's Market Cap is $10.9B, based on as-reported figures from SEC (XBRL) filings.
What is Glaukos Corporation's Enterprise Value?
Glaukos Corporation's Enterprise Value is $10.9B, based on as-reported figures from SEC (XBRL) filings.
What is Glaukos Corporation's Price / Sales?
Glaukos Corporation's Price / Sales is 17.8×, based on as-reported figures from SEC (XBRL) filings.
What is Glaukos Corporation's EV / Revenue?
Glaukos Corporation's EV / Revenue is 17.7×, based on as-reported figures from SEC (XBRL) filings.
What is Glaukos Corporation's EV / EBITDA?
Glaukos Corporation's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Glaukos Corporation's Revenue (TTM)?
Glaukos Corporation's Revenue (TTM) is $612.8M, based on as-reported figures from SEC (XBRL) filings.
What is Glaukos Corporation's Net Income (TTM)?
Glaukos Corporation's Net Income (TTM) is -$188.0M, based on as-reported figures from SEC (XBRL) filings.
What is Glaukos Corporation's EBITDA?
Glaukos Corporation's EBITDA is -$151.4M, based on as-reported figures from SEC (XBRL) filings.
What is Glaukos Corporation's Diluted EPS (TTM)?
Glaukos Corporation's Diluted EPS (TTM) is -3.19, based on as-reported figures from SEC (XBRL) filings.
What is Glaukos Corporation's EBITDA Margin?
Glaukos Corporation's EBITDA Margin is -24.7%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Net sales
YoY growth+49.5%+41.2%+35.7%+38.1%
Cost of sales
Gross profit
% of revenue81.7%77.9%-1.1%78.4%
Operating expenses:
Selling, general and administrative
Research and development
Acquired in-process research and development———
Total operating expenses
% of revenue91.0%91.0%96.7%90.7%
Loss from operations
% of revenue-9.3%-13.2%-97.7%-12.3%
Non-operating income (expense):
Interest income
Interest expense
Other (expense) income, net
Total non-operating (expense) income
Loss before taxes
Income tax provision
Net loss
% of revenue-9.9%-13.1%-93.4%-12.2%
Basic net loss per share (in dollar per share)
Diluted net loss per share (in dollar per share)